title: Long progression-free survival with afatinib in a patient with EGFR-unknown lung adenocarcinoma after erlotinib failure: a case report.
abstract: Important therapeutic advances for patients with advanced non-small cell lung cancer (NSCLC) have recently occurred, and the development of targeted therapy has revolutionized the treatment of these patients. We report the case of an NSCLC patient with unknown EGFR mutation status who developed resistance to erlotinib and was treated with afatinib. After 19 months of therapy with afatinib, the patient is still in treatment and maintains stable disease. Emerging resistance to reversible TKIs is a significant problem. Oral irreversible TKIs such as afatinib may offer an effective treatment option after failure with reversible TKIs.
authors.affiliation: Oncology Unit, Antonio Cardarelli Hospital, Naples - Italy.
authors.forename: Maria Giuseppa
authors.initials: MG
authors.lastname: Vitale
authors.forename: Sarah
authors.initials: S
authors.lastname: Scagliarini
authors.forename: Ferdinando
authors.initials: F
authors.lastname: Riccardi
authors.forename: Carmela
authors.initials: C
authors.lastname: Barbato
authors.forename: Manuela
authors.initials: M
authors.lastname: Otero
authors.forename: Carmela
authors.initials: C
authors.lastname: Mocerino
authors.forename: Francesca
authors.initials: F
authors.lastname: Ambrosio
authors.forename: Giacomo
authors.initials: G
authors.lastname: Cartenì
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics; D000077192:Adenocarcinoma of Lung; D000077716:Afatinib; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D066246:ErbB Receptors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use*; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077716:Afatinib; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors